Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
The Medicines Transparency Alliance Saul Walker Senior Policy Advisor, Access to Medicines Health Services Team Pharmaceutical markets • Public and private • International and local interactions • Information asymmetry • Manufacturer/(regulator)/purchaser • Wholesaler/Retailer • Prescriber/(Dispenser)/Patient • Lack of information • Irrational – unaligned incentives Page 2 The hypothesis … Transparency Validated Information & Appropriate Disclosure Mutual Accountability Multi-stakeholder disclosure & scrutiny Efficiency (public/private) Better policies, improved business practice & stronger implementation Page 3 Medicines Transparency Alliance 7 countries committed to work across government, private sector and civil society to disclose data on medicines price, quality, availability and promotion Country Priorities • Commit to disclosure and multi- stakeholder approach • Must include CSOs and private sector • Decide where to locate secretariat and stakeholder group • Agree priority areas and work plan • Guidance on disclosure from International Secretariat • Methodologies and technical support Page 5 The Pilot Pilot New validated data on pharmaceutical sector Disclosure of data and scrutiny by multistakeholder group Development of policy options Improved information for management ££, toolkit & technical support Policy change and implementation Changes in drug prices, availability, quality and/or promotion Improved processes. Policy research, shared learning Sector plans, domestic and CPs Page 6 Priorities chosen by countries Activity area Private sector mapping national medicines / health framework legislation quality / regulation evidence based selection & treatment guidelines procurement distribution / supply chain rational use of medicines prices, affordability medicines & insurance systems promotion operational research website, disseminate findings involving the media PE GH ZM UG JO KG PH v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v v Page 7 Data disclosure (in addition to baseline) • Pricing (Peru and Uganda) • Availability and promotion (Jordan and Zambia); • Transparency and accountability (Philippines - GGM) • Quality (Kyrgyzstan and Ghana); • Health insurance data mining (Ghana) • RUM (Uganda and Jordan) Page 8 Progress and Next Steps • All countries have agreed work plans – took longer than we expected • Implementation now underway – focus on newly disclosing & using information • Baseline surveys underway • Sector scan, availability, multi-stakeholder working – significant new data resources • Process evaluation 1Q10 – inform decisions and design for post-pilot Page 9 Questions • Disclosure – what, when and to whom? • Multi-stakeholder approach or multi- stakeholder analysis? • Catalysing support from others? • Adding value or adding confusion? Page 10 www.medicinestransparency.org Page 11